Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
The Pharma Data
DECEMBER 8, 2020
The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.
Let's personalize your content